Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 8Neoplasm Metastasis 4Neoplasms 3Melanoma 2Colorectal Neoplasms 2Breast Neoplasms 2Thymoma 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Disease Progression 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Biliary Tract Neoplasms 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 2toripalimab 1sintilimab 1pemigatinib 1osimertinib 1durvalumab 1Vinorelbine 1Platinum Compounds 1Nivolumab 1Ipilimumab 1Drug Therapy 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non Small Cell Lung Cancer × AZD 6244 × Thoracic × Clear all
NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

AstraZeneca

Phase 1 Active not recruiting
344 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡